Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Novel agents for chronic lymphocytic leukemia.

Wu M, Akinleye A, Zhu X.

J Hematol Oncol. 2013 May 16;6:36. doi: 10.1186/1756-8722-6-36. Review.

2.

Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.

Aivado M, Schulte K, Henze L, Burger J, Finke J, Haas R.

Semin Oncol. 2002 Aug;29(4 Suppl 13):19-22.

PMID:
12170428
3.

Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.

Giannopoulos K, Mertens D, Stilgenbauer S.

Expert Opin Pharmacother. 2011 Dec;12(18):2857-64. doi: 10.1517/14656566.2011.635644. Review.

PMID:
22098228
4.

[Chemotherapy-free treatment of chronic lymphocytic leukemia?].

Wendtner CM.

Dtsch Med Wochenschr. 2013 Oct;138(41):2104-6. doi: 10.1055/s-0033-1349501. Epub 2013 Oct 1. Review. German.

PMID:
24085367
5.

Bendamustine in the treatment of chronic lymphocytic leukemia.

Knauf W.

Expert Rev Anticancer Ther. 2009 Feb;9(2):165-74. doi: 10.1586/14737140.9.2.165. Review.

PMID:
19192955
6.

Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.

Lin TS.

Clin Lymphoma Myeloma. 2008 Aug;8 Suppl 4:S137-43. doi: 10.3816/CLM.2008.s.009. Review.

PMID:
18952544
7.

Lenalidomide alone and in combination for chronic lymphocytic leukemia.

Chen CI.

Curr Hematol Malig Rep. 2013 Mar;8(1):7-13. doi: 10.1007/s11899-012-0146-x. Review.

PMID:
23254517
8.

Emerging immunological drugs for chronic lymphocytic leukemia.

Robak P, Smolewski P, Robak T.

Expert Opin Emerg Drugs. 2015 Sep;20(3):423-47. doi: 10.1517/14728214.2015.1046432. Epub 2015 Jul 11. Review.

PMID:
26153226
9.

Bendamustine (Treanda) for CLL and NHL.

[No authors listed]

Med Lett Drugs Ther. 2008 Nov 17;50(1299):91-2. No abstract available. Erratum in: Med Lett Drugs Ther. 2008 Dec 1;50(1300):96.

PMID:
19008789
10.

Lenalidomide in CLL: what is the optimal dose?

Wendtner CM.

Clin Adv Hematol Oncol. 2011 Mar;9(3):220-4. No abstract available.

PMID:
21475128
11.

Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.

Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM.

J Clin Oncol. 2014 Sep 20;32(27):3039-47. Review.

12.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
13.

Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia.

Haskova Z, Whitacre MN, Dede KA, Lee JM, Trulli SH, Ciucci M, Toso JF, White JR, Jonak ZL.

Br J Haematol. 2012 Feb;156(3):402-4. doi: 10.1111/j.1365-2141.2011.08829.x. Epub 2011 Aug 18. No abstract available.

PMID:
21848524
14.

[Application of lenalidomide in chronic lymphocytic leukemia].

Lei W, Zhou KS, Li YF.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Apr;22(2):565-8. doi: 10.7534/j.issn.1009-2137.2014.02.056. Review. Chinese.

PMID:
24763044
15.

Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL).

Hill BT, Caimi P, Kindwall-Keller T, Habecker B, Kalaycio M.

Br J Haematol. 2014 Jan;164(2):297-9. doi: 10.1111/bjh.12604. Epub 2013 Oct 17. No abstract available.

PMID:
24131326
16.

Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.

Friedberg JW.

Leuk Lymphoma. 2009 Sep;50(9):1399-400. No abstract available.

PMID:
19811324
17.

Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.

Dennie TW, Kolesar JM.

Clin Ther. 2009;31 Pt 2:2290-311. doi: 10.1016/j.clinthera.2009.11.031. Review.

PMID:
20110042
18.

Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.

Zaja F, Mian M, Volpetti S, Visco C, Sissa C, Nichele I, Castelli M, Ambrosetti A, Puglisi S, Fanin R, Cortelazzo S, Pizzolo G, Trentin L, Rodeghiero F, Paolini R, Vivaldi P, Sancetta R, Isola M, Semenzato G.

Am J Hematol. 2013 Nov;88(11):955-60. doi: 10.1002/ajh.23546. Epub 2013 Sep 9.

19.

Lenalidomide and chronic lymphocytic leukemia.

González-Rodríguez AP, Payer AR, Acebes-Huerta A, Huergo-Zapico L, Villa-Alvarez M, Gonzalez-García E, Gonzalez S.

Biomed Res Int. 2013;2013:932010. doi: 10.1155/2013/932010. Epub 2013 Sep 19. Review.

20.

Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.

Iannitto E, Morabito F, Mancuso S, Gentile M, Montanini A, Augello A, Bongarzoni V, D'Arco A, Di Renzo N, Fazzi R, Franco G, Marasca R, Mulè A, Musso M, Musto P, Pennese E, Piccin A, Rota-Scalabrini D, Visani G, Rigacci L.

Br J Haematol. 2011 May;153(3):351-7. doi: 10.1111/j.1365-2141.2011.08597.x. Epub 2011 Mar 4.

PMID:
21371003
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk